Email This Article

Headlines & Perspectives
GenVec Stock Hit by Pancreas Study's Details
By Adam Feuerstein
11/19/08 - 01:40 PM EST
GenVec's shares sank Wednesday despite what the company said was a positive update on its experimental pancreatic cancer drug TNFerad.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,226.94 1,093.07 2,154.06 34.86
Oil *
77.65
UP
203.52
UP
23.77
UP
41.62
DOWN
0.17
10 Yr
3.49%
SPDR Gold
108.19
+2.03%
+2.22%
+1.97%
-0.49%
Data delayed 20 minutes

Brokerage Partners